LUP Stock Overview
An investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for LUP from our risk checks.
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Luye Pharma Group Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$0.28 |
| 52 Week High | HK$0.40 |
| 52 Week Low | HK$0.25 |
| Beta | 0.87 |
| 1 Month Change | 2.21% |
| 3 Month Change | 3.73% |
| 1 Year Change | -17.75% |
| 3 Year Change | -21.02% |
| 5 Year Change | -42.32% |
| Change since IPO | -59.36% |
Recent News & Updates
Recent updates
Shareholder Returns
| LUP | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 2.2% | 2.0% | 4.1% |
| 1Y | -17.8% | -10.7% | 17.2% |
Return vs Industry: LUP underperformed the German Pharmaceuticals industry which returned -11.2% over the past year.
Return vs Market: LUP underperformed the German Market which returned 16.4% over the past year.
Price Volatility
| LUP volatility | |
|---|---|
| LUP Average Weekly Movement | 4.9% |
| Pharmaceuticals Industry Average Movement | 4.2% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 12.1% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: LUP has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: LUP's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 5,234 | Dian Bo Liu | www.luye.cn |
Luye Pharma Group Ltd., an investment holding company, develops, produces, markets, and sells pharmaceutical products worldwide. The company offers Lipusu for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Tiandida for ovarian or non-small cell lung cancer; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surgery, and for venous reflux disorders; Beixi, an acarbose capsule for Type 2 diabetes; Apleek Transdermal Patch for contraception; Rivastigmine Transdermal Patch for the treatment of Alzheimer’s disease; and Seroquel and Seroquel XR for the treatment of schizophrenia and manic episodes of bipolar affective disorders.
Luye Pharma Group Ltd. Fundamentals Summary
| LUP fundamental statistics | |
|---|---|
| Market cap | €1.07b |
| Earnings (TTM) | €97.38m |
| Revenue (TTM) | €797.97m |
11.0x
P/E Ratio1.3x
P/S RatioIs LUP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LUP income statement (TTM) | |
|---|---|
| Revenue | CN¥6.31b |
| Cost of Revenue | CN¥1.97b |
| Gross Profit | CN¥4.34b |
| Other Expenses | CN¥3.57b |
| Earnings | CN¥770.46m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Mar 28, 2025
| Earnings per share (EPS) | 0.20 |
| Gross Margin | 68.73% |
| Net Profit Margin | 12.20% |
| Debt/Equity Ratio | 66.6% |
How did LUP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/18 08:45 |
| End of Day Share Price | 2025/03/18 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Luye Pharma Group Ltd. is covered by 20 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ling Zhang | BNP Paribas Securities (Asia) |
| Jessica Li | BofA Global Research |
| Lok Kwan Chiu | CCB International Securities Limited |